Topic: monoclonal antibody
Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.
Just 48 hours after filing a $115 million IPO, Forty Seven unveiled the first data for its CD47 antibody at ASCO, pledging moves into phase 2 studies.
Syngene partnered with Zumutor to screen antigens against Zumutor’s human antibody libraries, to discover antibody clones for additional development.
Early data from Zymeworks showed its lead bispecific antibody hit an overall response rate of 36%, as a single agent for a variety of HER2+ cancers.
Frances Rena Bahjat, BMS’ former director of in vivo studies, joined Apexigen in a newly created role.
Abpro postponed its $69 million IPO, according to reports, delaying capital it hoped would support its first clinical trials planned for next year.
Genentech scientists used an antibody to kill E. coli bacteria by blocking the enzyme BamA.
Median PFS is still ticking up in the trial of the CD19 antibody, adding weight to MorphoSys’ claims MOR208 can hold its own against CAR-T therapies.
Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.
The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.